YELIVA – ABC294640 Trial

Dear Fred-

Any updates?  Are you still in the trial for Yeliva?  Anyone else on here been on it?

I had my second “on trial” scan last Saturday and reviewed the results at Emory yesterday.  So far, still good: no progression. Excerpts from the summary of the radiologist’s “impressions”:

• Stable
• Stable
• Decreased
• No new or enlarging sites of disease

I’ve now been on the trial for 16 weeks. No side effects to speak of. I’ll have bloodwork next the week of 2/20 and the next scan should be on or about 3/16.  I’ll continue to report results/status and welcome feedback from anyone else on this trial. Thanks.

Fred

Well, it’s still early, but decent results so far. I had my first “on trial” scan on December 2, and reviewed the results with Dr. Akce, my Emory oncologist and the PI for this trial at Emory, on December 5. The tumor had earlier been measured as 2.6 x 1.6 cm. In this scan it was reported at 2.8 x 1.8 cm, within the limits to conclude no progression and for me to remain on the trial. Dr. Akce also noted that it has been very difficult to precisely measure this tumor and there was a pretty good chance it really hasn’t grown at all. There has been no spread, and I have had really no side effects from the trial drug.

I will have my next scan at the end of January.

Fred

Hi Fred,

Thank you for the update, and congratulations on starting this trial.  Fingers crossed the trial med brings you great results!

Take care, regards, Mary

Hi Fred,

Thank you for your note.  I looked through the discussion board and while there is discussion about possibly seeking this treatment, I did not find any patients who wrote about being treated with Yeliva.  I also contacted a caregiver who was looking into it, and that patient did not in the end pursue Yeliva either.  Hopefully, if a patient or caregiver who is under Yeliva treatment sees this string, they will post on their experience.

If you do enroll in this trial, I hope you will keep us posted.

Regards, Mary

A bit more, Mike….. Angiogenesis plays a critical role in the growth and spread of cancer. A blood supply is necessary for tumors to grow beyond a few millimeters in size. Tumors can cause this blood supply to form by giving off chemical signals that stimulate angiogenesis. Tumors can also stimulate nearby normal cells to produce angiogenesis signaling molecules. The resulting new blood vessels “feed” growing tumors with oxygen and nutrients, allowing the cancer cells to invade nearby tissue, to move throughout the body, and to form new colonies of cancer cells, called metastases.

Because tumors cannot grow beyond a certain size or spread without a blood supply, scientists are trying to find ways to block tumor angiogenesis. They are studying natural and synthetic angiogenesis inhibitors, also called antiangiogenic agents, with the idea that these molecules will prevent or slow the growth of cancer.

Hugs
Marion